EP1750805A2 - Medicaments a base de pyrroloquinoline quinone destines au traitement de lesions cardiaques et procedes d'utilisation correspondants - Google Patents

Medicaments a base de pyrroloquinoline quinone destines au traitement de lesions cardiaques et procedes d'utilisation correspondants

Info

Publication number
EP1750805A2
EP1750805A2 EP05745030A EP05745030A EP1750805A2 EP 1750805 A2 EP1750805 A2 EP 1750805A2 EP 05745030 A EP05745030 A EP 05745030A EP 05745030 A EP05745030 A EP 05745030A EP 1750805 A2 EP1750805 A2 EP 1750805A2
Authority
EP
European Patent Office
Prior art keywords
subject
pyrroloquinoline quinone
pqq
injury
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05745030A
Other languages
German (de)
English (en)
Inventor
Paul J. Davis
Joel S. Karliner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLF Medical Technology Acceleration Program Inc
Original Assignee
CLF Medical Technology Acceleration Program Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLF Medical Technology Acceleration Program Inc filed Critical CLF Medical Technology Acceleration Program Inc
Publication of EP1750805A2 publication Critical patent/EP1750805A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne des compositions comprenant un pyrroloquinoline quinone sensiblement purifié, utilisées dans des procédés de traitement et de prévention des lésions cardiaques provoquées par l'hypoxie ou l'ischémie. L'invention concerne également des procédés destinés au traitement ou à la prévention de lésions cardiaques, qui consiste à administrer la composition de l'invention à un patient humain.
EP05745030A 2004-05-05 2005-05-05 Medicaments a base de pyrroloquinoline quinone destines au traitement de lesions cardiaques et procedes d'utilisation correspondants Withdrawn EP1750805A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56835304P 2004-05-05 2004-05-05
US61750804P 2004-10-08 2004-10-08
PCT/US2005/015742 WO2005107871A2 (fr) 2004-05-05 2005-05-05 Medicaments a base de pyrroloquinoline quinone destines au traitement de lesions cardiaques et procedes d'utilisation correspondants

Publications (1)

Publication Number Publication Date
EP1750805A2 true EP1750805A2 (fr) 2007-02-14

Family

ID=34968662

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05745030A Withdrawn EP1750805A2 (fr) 2004-05-05 2005-05-05 Medicaments a base de pyrroloquinoline quinone destines au traitement de lesions cardiaques et procedes d'utilisation correspondants

Country Status (5)

Country Link
EP (1) EP1750805A2 (fr)
JP (1) JP2007536256A (fr)
AU (1) AU2005240650A1 (fr)
CA (1) CA2565616A1 (fr)
WO (1) WO2005107871A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535410A (ja) * 2006-05-02 2009-10-01 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド ピロロキノリンキノンおよびその使用
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN110870866A (zh) * 2018-09-03 2020-03-10 浙江医药股份有限公司新昌制药厂 吡咯喹啉醌在制备用于防治急性高原反应和急性高原低氧损伤的药物中的应用
IT202000025603A1 (it) * 2020-10-28 2022-04-28 Longeva Health S R L Composizione per prevenire e trattare lo scompenso e/o l’insufficienza cardiaca

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979073A4 (fr) * 1997-03-31 2004-04-07 Childrens Medical Center Nitrosylation effectuee pour inactiver des enzymes apoptotiques
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005107871A2 *

Also Published As

Publication number Publication date
CA2565616A1 (fr) 2005-11-17
JP2007536256A (ja) 2007-12-13
WO2005107871A2 (fr) 2005-11-17
AU2005240650A1 (en) 2005-11-17
WO2005107871A3 (fr) 2006-12-21

Similar Documents

Publication Publication Date Title
US20080221145A1 (en) Pyrroloquinoline quinone drugs for treatement of cardiac injury and methods of use thereof
US20100160367A1 (en) Pharmaceutical compositions containing pyrroloquinoline quinone and nephroprotectant for treating ischemia reperfusion injuries
US6689774B2 (en) Zinc ionophores as therapeutic agents
US6174875B1 (en) Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
KR20030014208A (ko) 티올계 화학보호제 화합물의 투여
CA2550505A1 (fr) Composes antagonistes du cuivre
EP2068879A2 (fr) Médicaments à base de pyrroloquinoléine quinone, et leurs procédés d'utilisation
CA2716019C (fr) Agents antitumoraux avec une structure de benzophenanthridine et formulations les contenant
EP3352745B1 (fr) Combinaison de dofétilide et de mexilétine pour la prévention et le traitement de la fibrillation auriculaire
JP2023518775A (ja) シクロフィリン阻害剤およびその使用
WO1999051223A1 (fr) Ansamycines benzoquinoides pour le traitement d'une crise ou d'un arret cardiaque
WO2005107871A2 (fr) Medicaments a base de pyrroloquinoline quinone destines au traitement de lesions cardiaques et procedes d'utilisation correspondants
CA2455246C (fr) Preparation de drogues comprenant de l'acide .alpha.-lipoique, de l'ambroxol et/ou des inhibiteurs de l'enzyme de conversion de l'angiotensine (ace) et leur utilisation pour le traitement de maladies neurodegeneratives
WO2009015561A1 (fr) Utilisation de léonurine et compositions
US20050267143A1 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
IL296586A (en) Cyclophilin inhibitors and their uses
AU2013247291A1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
US20030229114A1 (en) Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
JP2000510114A (ja) 抗酸化剤化合物
US6455553B1 (en) Method for treating a demyelinating condition
KR20210148078A (ko) 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
EP1189604A2 (fr) Ionophores de zinc utilises comme agents anti-apoptose
US20030032676A1 (en) Drugs for treatment of cerebral injury and methods of use thereof
JP4393863B2 (ja) 視神経細胞保護剤
WO2003099282A1 (fr) Composes a base de pyrroloquinoline quinone utilises comme neuroprotecteurs de la substance blanche et techniques d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111201